证券研究报告 宏观专题报告 / 2025.10.28 分析师 张伟 SAC 证书编号：S0160525060002 zhangwei04@ctsec.com 联系人 连桐杉 liants@ctsec.com 核心观点 ❖ 工业企业利润率为何维持正增：9 月，工业经营量价齐升、利润率正增， 利润率是主要支撑项，但拉动幅度边际下降。PPI、工业企业利润率的低基数 效应仍然是利润增速回升的主要原因。 ❖ 分结构来看： 请阅读最后一页的重要声明！ 低基数告一段落——9 月工业利润点评 ❖ 上游采矿业"增利不增收"，多数采矿行业营收仍然保持较大幅度的下滑，但 利润率近三个月均在所有行业的前列，可能与"反内卷"政策的推进有较大的 关系。 ❖ 处于中上游的原材料加工业和中间品制造业在所有行业中利润率最薄，这可 能也是"反内卷"的结果之一。上游原材料提价但下游需求仍然偏弱，价格传 导存在阻碍，使得"原材料-产成品"价格剪刀差不断拉大（详见报告《反内 卷的结构影响：预防性备采与价格剪刀差》），挤压了加工制造环节的利润空 间。 ❖ 装备制造业的营收增长整体领先其他行业，利润率也并不弱，今年以来一直 保持了较高的景气度，仍然受益于 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported a revenue of 15.917 billion yuan for the first three quarters of 2025, a year-on-year increase of 0.19%, while the net profit attributable to shareholders decreased by 24.29% to 496 million yuan [8][9] - The average net profit per ton for the first three quarters was 97.3 yuan, showing a year-on-year decline of 7.7% but a quarter-on-quarter increase of 3.7% [9] - The company has invested in nearly 2,500 lightweight welding robots and rail-type robotic welding stations, which are expected to gradually show cost reduction and efficiency improvement [9] - The forecast for revenue from 2025 to 2027 is 22.778 billion, 24.270 billion, and 25.862 billion yuan respectively, with net profits of 773 million, 938 million, and 1.125 billion yuan [9] Financial Performance Summary - Revenue for 2023 is projected at 23.539 billion yuan, with a growth rate of 18.6%, followed by a decline of 8.6% in 2024 [5][10] - The net profit for 2023 is estimated at 1.179 billion yuan, with a growth rate of 1.4%, and is expected to decrease by 34.5% in 2024 [5][10] - The earnings per share (EPS) for 2023 is 1.71 yuan, projected to drop to 1.12 yuan in 2024 and remain at 1.12 yuan in 2025 [5][10] - The price-to-earnings (PE) ratio is expected to be 17.2 in 2025, decreasing to 14.2 in 2026 and 11.8 in 2027 [5][10]

小核酸创新转型 前沿生物-U(688221) 证券研究报告 化学制药 / 公司深度研究报告 / 2025.10.28 | 投资评级:增持(首次) | | --- | | 基本数据 | 2025-10-27 | | --- | --- | | 收盘价(元) | 14.22 | | 流通股本(亿股) | 3.75 | | 每股净资产(元) | 2.79 | | 总股本(亿股) | 3.75 | 最近 12 月市场表现 -13% 39% 90% 142% 194% 245% 前沿生物-U 沪深300 上证指数 化学制药 分析师 华挺 SAC 证书编号：S0160523010002 huating@ctsec.com 联系人 宋田田 songtt@ctsec.com 核心观点 盈利预测 | [币种Table_FinchinaSimple] (人民币) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 114 | 129 | 210 | 322 | 454 | | 收入增长率(%) ...

Investment Rating - The investment rating for the company is "Add" (maintained) [2] Core Views - The company reported a significant increase in revenue and net profit for Q3 2025, with revenue reaching 1.52 billion yuan, a year-on-year growth of 25.33%, and net profit of 431 million yuan, a year-on-year growth of 35.42% [7] - The transition from "office tool software" to "AI office intelligent platform" is viewed positively, with projected revenues of 5.99 billion, 7.11 billion, and 8.55 billion yuan for 2025, 2026, and 2027 respectively [7] - The company maintains a high gross margin of 86.46% and a robust cash flow, with net cash flow from operating activities at 538 million yuan, a year-on-year increase of 19.3% [7] Financial Performance Summary - For the first three quarters of 2025, the company achieved a revenue of 4.178 billion yuan, a year-on-year increase of 15.21%, and a net profit of 1.178 billion yuan, a year-on-year increase of 13.32% [7] - The company’s revenue growth rate is projected to be 17.0% in 2025, 18.7% in 2026, and 20.1% in 2027 [6] - The earnings per share (EPS) is expected to grow from 4.04 yuan in 2025 to 5.85 yuan in 2027, with corresponding price-to-earnings (PE) ratios decreasing from 78.5x to 54.2x over the same period [6][7] Business Segment Performance - The WPS 365 business segment showed remarkable growth, with revenue increasing by 71.61% year-on-year to 201 million yuan, driven by enhanced collaboration and AI features [7] - The personal WPS business generated 899 million yuan in revenue, reflecting an 11.18% year-on-year growth, supported by improved user penetration through AI and localized services [7] Future Outlook - The company is expected to continue benefiting from government and enterprise orders, particularly in the context of digital transformation initiatives [7] - The projected net profit for 2025 is 1.871 billion yuan, with further increases to 2.142 billion yuan in 2026 and 2.709 billion yuan in 2027 [6][7]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company achieved a revenue of 1.11 billion yuan in Q3 2025, representing a year-on-year growth of 15.85%, and a net profit of 216 million yuan, up 30.19% year-on-year. For the first three quarters of 2025, the company reported a revenue of 3.241 billion yuan, a growth of 8%, and a net profit of 581 million yuan, an increase of 13.93% year-on-year [7] - The company is focusing on chronic disease areas, with successful sales expansion. New products have been approved through national medical insurance negotiations, and the company is enhancing market coverage through a multi-channel approach, including e-commerce [7] - The research and development pipeline is robust, with 74 new drugs in development, including 51 chemical drugs and 23 biological drugs. The clinical trials for JK07 are progressing, with expectations for key data release in mid-2026 [7] - The company is projected to achieve revenues of 4.454 billion yuan, 5.344 billion yuan, and 6.253 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 628 million yuan, 690 million yuan, and 796 million yuan [7] Financial Summary - For 2023A, the company reported a revenue of 3,365 million yuan, with a revenue growth rate of -3.4%. The net profit was 580 million yuan, with a net profit growth rate of -9.0% [6] - The projected earnings per share (EPS) for 2025E is 0.56 yuan, with a price-to-earnings (PE) ratio of 89.6 [6] - The return on equity (ROE) is expected to be 7.1% in 2025E, with a price-to-book (PB) ratio of 6.4 [6]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company has shown a recovery in domestic business growth, with significant increases in revenue and net profit in the third quarter of 2025. The revenue reached 142 million yuan, a year-on-year increase of 17.44%, and the net profit was 25.38 million yuan, up 268.13% year-on-year [7] - The international business continues to grow, with Implanet achieving revenue of 291.59 million euros in the third quarter, a year-on-year increase of 26.37%. The U.S. market contributed 106.20 million euros, up 22.21% year-on-year [7] - The company is expected to achieve revenue of 590 million yuan in 2025, with a net profit of 33 million yuan, corresponding to a PE ratio of 205.2 times [7] Financial Performance - For the fiscal year 2023, the company reported revenue of 460 million yuan, with a projected revenue of 590 million yuan for 2025, reflecting a growth rate of 30.1% [6][8] - The net profit for 2023 was 96 million yuan, with an expected increase to 33 million yuan in 2025, indicating a significant recovery from previous years [6][8] - The company's earnings per share (EPS) is projected to rise from 0.38 yuan in 2023 to 0.10 yuan in 2025 [6][8] Market Performance - The company's stock has experienced a decline of 26% over the past 12 months, compared to the Shanghai and Shenzhen 300 index [4]

投资评级:增持(维持) | 基本数据 | 2025-10-27 | | --- | --- | | 收盘价(元) | 63.87 | | 流通股本(亿股) | 7.95 | | 每股净资产(元) | 14.23 | | 总股本(亿股) | 8.00 | 最近 12 月市场表现 无惧关税影响，三季度业绩延续上半年增速 豪迈科技(002595) 证券研究报告 专用设备 / 公司点评 / 2025.10.28 -9% 0% 9% 18% 27% 36% 豪迈科技 沪深300 上证指数 分析师 佘炜超 SAC 证书编号：S0160522080002 shewc@ctsec.com 分析师 谢铭 SAC 证书编号：S0160523010001 xieming@ctsec.com 分析师 孟欣 SAC 证书编号：S0160523090002 mengxin@ctsec.com 分析师 何兵 SAC 证书编号：S0160525080007 hebing@ctsec.com 相关报告 1. 《模具、零部件、机床业务三轮驱动，稳 步增长》 2025-09-01 2. 《产能产品全力运行，三大业务实现稳步 增长》 2025-03 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company has experienced a decline in revenue and net profit due to continued weak downstream demand and tightened credit policies. The gross margin has improved slightly due to stable raw material prices and ongoing optimization of product and channel structures [7] - The company has proactively adjusted product prices in response to market conditions, indicating a potential recovery in profitability as the competitive landscape improves. This includes price increases of 3%-13% for certain waterproof coatings and 3%-7% for waterproof membranes [7] - The forecast for net profit from 2025 to 2027 shows a recovery trend, with expected net profits of 0.42 million, 1.28 million, and 2.09 million respectively, reflecting growth rates of -5.81%, 207.23%, and 64.19% [7] Financial Performance Summary - For the first three quarters of 2025, the company reported a revenue of 4.703 billion, a decrease of 8.43% year-on-year, and a net profit of 0.20 billion, down 84.08% year-on-year. The Q3 revenue was 1.483 billion, down 10.93% year-on-year, with a net profit of -0.27 billion [7] - The company's gross margin for Q3 was 23.56%, an increase of 1.38 percentage points year-on-year, while the operating cash flow showed a net outflow of 0.824 billion, which improved by 0.680 billion year-on-year [7][8] - The financial forecasts indicate a revenue decline in 2024 and 2025, with expected revenues of 6.829 billion and 6.327 billion respectively, followed by a recovery in 2026 and 2027 [6][8]

天目湖(603136) 证券研究报告 旅游及景区 / 公司点评 / 2025.10.27 投资评级:增持(维持) 核心观点 | 基本数据 | 2025-10-24 | | --- | --- | | 收盘价(元) | 11.50 | | 流通股本(亿股) | 2.70 | | 每股净资产(元) | 5.03 | | 总股本(亿股) | 2.70 | 最近 12 月市场表现 毛利率稳定，销售费用投放增加致净利率下降 -9% -3% 3% 9% 16% 22% 天目湖 沪深300 分析师 耿荣晨 SAC 证书编号：S0160525070002 gengrc@ctsec.com 分析师 周诗琪 SAC 证书编号：S0160525060006 zhousq@ctsec.com 相关报告 1. 《Q2 收入承压，盈利能力优化》 2025- 08-25 2. 《三季度极端天气扰动严重，关注动物王 国建设》 2024-10-28 3. 《节假日项目景气度不减，关注国资持续 赋能》 2024-08-30 盈利预测 | [币种Table_FinchinaSimple] (人民币) | 2023A | 2024A | 2025E ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported a revenue of 25.874 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 9.38%. The net profit attributable to shareholders was 1.404 billion yuan, a slight decrease of 0.49% year-on-year [8][9] - The company has shown continuous growth in production and sales, with a total output of 1.1945 million tons of aluminum plates, strips, foils, and profiles, marking an 8.6% increase year-on-year. The sales volume reached 1.1875 million tons, up 8.2% year-on-year [8][9] - The company is undergoing a high-end transformation, which is expected to enhance its profitability and operational efficiency. The focus on high-value-added products and green manufacturing is anticipated to further reduce costs and improve margins [8][9] Financial Performance Summary - For 2023, the company achieved a revenue of 26.442 billion yuan, with a projected revenue growth rate of 22.2% for 2024 and 14.1% for 2025. The net profit for 2023 was 1.347 billion yuan, with expected growth rates of 29.8% in 2024 and 11.8% in 2025 [7][10] - The earnings per share (EPS) for 2023 was 1.31 yuan, with projections of 1.46 yuan for 2024 and 1.57 yuan for 2025. The price-to-earnings (PE) ratio is expected to be 9.4 for 2025 [7][10] - The company’s return on equity (ROE) is projected to be 10.2% in 2025, indicating a strong financial performance [7][10] Production and Profitability Insights - The company’s processing profit per ton of aluminum products has been on the rise, reaching 1,509.1 yuan in Q3 2025, driven by high-end transformation and increased processing fees [8][9] - The company has made significant advancements in its new energy materials layout and high-end intelligent manufacturing, which are expected to enhance its production capacity in high-end aluminum materials [8][9] Future Projections - The company is expected to achieve revenues of 36.870 billion yuan in 2025, 40.027 billion yuan in 2026, and 42.769 billion yuan in 2027. The net profit attributable to shareholders is projected to be 1.954 billion yuan in 2025, 2.206 billion yuan in 2026, and 2.429 billion yuan in 2027 [8][9]